Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Robert, Caroline; Flaherty, Keith T.

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

Autor(en):

Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Robert, Caroline; Flaherty, Keith T.

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

Journal of Clinical Oncology (2023), Bd. 41, H. 29, S. 4621-4631

Verlagsangabe:

Philadelphia : Lippincott Williams & Wilkins

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.22.02322

ISSN:

0732-183X